RBC Capital analyst Leonid Timashev raised the firm’s price target on Nuvation Bio (NUVB) to $12 from $9 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB: